BIOMARKERS IN BLOOD PLASMA FOR COMBINED THERAPIES USING BEVACISUMAB IN THE TREATMENT OF BREAST CANCER

摘要

1. An in vitro method for determining whether a patient diagnosed with breast cancer is more or less suitable for treatment using anti-cancer therapy comprising an anti-VEGF antibody, comprising: (a) determining an expression level of at least one biomarker selected from the group consisting of E-selectin, ICAM-1 and VEGFR-3, in a sample obtained from the body of a patient diagnosed with breast cancer, and (b) identification of the patient as suitable to a greater or lesser extent for treatment using the use of anticancer therapy, including an anti-VEGF antibody, based on the expression level established according to subparagraph (a), when the expression level of the specified biomarker, equal to or higher than the reference level, indicates that the patient is more suitable for treatment using anticancer therapy , or the expression level of the indicated marker, lower than the reference level, indicates that the patient is less suitable for treatment using anticancer therapy. 2. The method according to claim 1, in which the question of the suitability of the patient for treatment using anticancer therapy is solved using survival without disease progression as a criterion. The method according to one of paragraphs. 1-2, where the method further includes treating the patient using anticancer therapy. 4. The method according to one of paragraphs. 1-2, wherein said anticancer therapy comprises an anti-VEGF antibody, an anti-HER2 antibody and taxane. An in vitro method for selecting a treatment for a patient diagnosed with breast cancer, the method comprising: (a) analyzing a biological sample from a patient, in which it is determined whether the patient has